top of page
Picture4.png

Llew Keltner M.D. Ph.D. Director Caravan Biologix

Picture2_edited.png
  • LinkedIn

Llew Keltner, M.D., Ph.D., has a 40-year career in biopharma drug and business development. He is Chief Executive Officer of EPISTAT, an international healthcare technology transfer, corporate risk management and healthcare strategy company that he founded in 1972. Dr. Keltner is a founder and CEO of OncoSCAR, the company leading the field in development of diagnostics and therapeutics based on the regulatory power of transposed portions of the human retrovirome. He was the Chief Executive Officer of AgonOx, a biotech company developing OX40 agonists for use in cancer therapy, from 2011 to 2013. He was the President of Novici Biotech, a privately-held gene and protein optimization firm in 2010 and 2011. Dr. Keltner was Chief Executive Officer and President of Light Sciences Oncology, a privately-held biotechnology company developing a late stage, light-activated therapy for hepatocellular cancer, other solid tumors, and benign prostatic hypertrophy from 2001 to 2010, and again serves in that role since 2019. From 1997 to 2004, Dr. Keltner was Chief Executive Officer of Metastat, a development-stage biotech company focused on cancer metastasis.

​

Dr. Keltner holds positions on the boards of Ergomed, Curetech, Vesselon, Infostat, BioQ Pharma, Oregon Life Sciences, Surgeon Training International, and OncoSCAR. He is a previous Director of Raptor Pharmaceuticals, where he served as Chairman (NASDAQ:RPTP), Light Sciences Corporation, Immunovaccine (TSX.V:IMV), Vital Choice, Thesis Technologies, Oread Companies, and MannKind Corporation (NASDAQ:MNKD). He has also been a scientific advisory board member at Heat Biologics, Pelican Therapeutics, Lifetime Corporation, ASB Meditest, Oread Laboratories, Hall-Kimbrell, Ajuta Bio, and aai Pharma. Dr. Keltner is an Associate Professor at Case Western Reserve School of Medicine, and a Guest Lecturer and Director in the Bioethics Program at Columbia University School of Medicine, and serves on the Advisory Board of BioEthics International. He is currently a member of the American Society of Clinical Oncology, American Association of Cancer Research, American Medical Association, International Association of Tumor Marker Oncology, American Association of Clinical Chemistry, and Drug Information Association. Dr. Keltner received an M.S. in Epidemiology and Biostatistics, a Ph.D. in Biomedical Informatics and an M.D. from Case Western Reserve University in Cleveland, Ohio. Dr. Keltner has also authored many research publications.

bottom of page